9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $219M | -$114M | 0.0% | -72.8% | -$73M | — | $113M |
| 2024 | $7M | -$274M | 0.0% | -4671.1% | -$251M | — | $84M |
| 2023 | $23M | -$113M | 0.0% | -574.9% | -$118M | — | $157M |
| 2022 | $51M | -$59M | 0.0% | -122.7% | -$91M | — | $69M |
| 2021 | $28M | -$50M | 0.0% | -179.9% | -$58M | — | $92M |
| 2020 | $20M | -$34M | 0.0% | -180.9% | $55M | — | $72M |
| 2019 | $0 | -$42M | — | — | -$41M | — | $34M |
| 2018 | — | -$34M | — | — | -$29M | — | $21M |
| 2017 | — | -$12M | — | — | -$14M | — | $6M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $7M | -$99M | 0.0% | -1654.6% | -$76M | — | $158M |
| Dec '25 | $11M | -$83M | 0.0% | -869.5% | -$91M | — | $113M |
| Sep '25 | $208M | $119M | 0.0% | 52.2% | $142M | — | $299M |
| Jun '25 | — | -$77M | — | — | -$63M | — | $115M |
| Mar '25 | — | -$72M | — | — | -$62M | — | $130M |
| Dec '24 | $7M | -$130M | 0.0% | -2059.1% | -$123M | — | $84M |
| Sep '24 | $0 | -$52M | — | — | -$50M | — | $400M |
| Jun '24 | $0 | -$53M | — | — | -$34M | — | $183M |
| Mar '24 | $0 | -$40M | — | — | -$45M | — | $108M |
| Dec '23 | $4M | -$34M | 0.0% | -1068.8% | -$25M | — | $157M |
| Sep '23 | $8M | -$27M | 0.0% | -417.1% | -$31M | — | $152M |
| Jun '23 | $4M | -$28M | 0.0% | -922.9% | -$34M | — | $103M |
| Mar '23 | $8M | -$24M | 0.0% | -333.5% | -$28M | — | $67M |
| Dec '22 | $4M | -$24M | 0.0% | -657.5% | -$23M | — | $69M |
| Sep '22 | $30M | $2M | 0.0% | 2.2% | -$25M | — | $102M |
| Jun '22 | $6M | -$22M | 0.0% | -384.5% | -$22M | — | $49M |
| Mar '22 | $11M | -$14M | 0.0% | -125.2% | -$20M | — | $55M |
| Dec '21 | $3M | -$18M | 0.0% | -620.2% | -$17M | — | $92M |
| Sep '21 | $9M | -$12M | 0.0% | -130.5% | -$13M | — | $108M |
| Jun '21 | $9M | -$11M | 0.0% | -126.2% | -$14M | — | $90M |
How the market has priced IDYA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ideaya Biosciences, Inc.'s revenue has grown 62.1% per year. These are computed facts, not advice.
As of FY2025, Ideaya Biosciences, Inc. reported — of total debt against $113M of cash.
In FY2025, gross margin was —, operating margin -72.8%, and net margin -52.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.